Insights

Adherium (ASX:ADR) share price rockets 53% on US FDA clearance

The company’s shares are hitting a new 6-month high…
The post Adherium (ASX:ADR) share price rockets 53% on US FDA clearance appeared first on The Motley Fool Australia. –

The Adherium Ltd (ASX: ADR) share price soared to dizzying heights today. This comes after the digital healthcare company announced it has received a 510(k) clearance from the United States Food and Drug Administration (FDA).

At the end of Thursday’s market close, Adherium shares finished up 53.33% to 2.3 cents.

Milestone achievement for Adherium

The Adherium share price surged today as investors were fighting to get a hold of the company’s shares.

According to its release, Adherium advised that the United States FDA has cleared the pathway for the company to begin commercialisation for Hailie Sensor.

The company’s next generation, Hailie Sensor are devices that attach to a patient’s Asthma or Chronic Obstructive Pulmonary Disease (COPD) medication inhaler. This allows caregivers to monitor medication use and capture clinical data whilst supporting the patient’s management and treatment journey.

Furthermore, the latest Hailie Sensor is designed for use with AstraZeneca’s Symbicort aerosol inhaler.

The total addressable market for treating Asthma and COPD patients in the United States is estimated to be around US$1.5 billion.

With the Hailie Sensor approved, this means that the FDA has granted 10 510(k) licences to Adherium for its devices. As such, the company has become a market leader in respiratory digital health.

Adherium stated that it intends to pursue multiple channels in order for Hailie Sensor to enter the market.

Adherium CEO, Rick Legleiter commented:

The FDA’s first clearance of our next generation Hailie sensors with physiological measures is a significant regulatory step for the business.

The stage is now set for physiological measures to be coupled with our existing adherence sensor capability giving us the total ‘one-two punch’ to deliver the best value proposition of any smart inhaler digital solution in the world.

…Adherium will expand its addressable respiratory medication market coverage and establish a preeminent business partnering position for providers, payors and digital health affiliates.

About the Adherium share price

Since this time last year, Adherium shares were mostly tracking lower until today, currently down 22%. Year-to-date, its shares are also in negative territory, down 14%.

Adherium presides a market capitalisation of roughly $54.3 million and has 2.1 billion shares on its registry.

The post Adherium (ASX:ADR) share price rockets 53% on US FDA clearance appeared first on The Motley Fool Australia.

Should you invest $1,000 in Adherium right now?

Before you consider Adherium, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Adherium wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

How does the A2 Milk (ASX:A2M) share price compare to the ASX 200 today?
Here are the 3 heaviest trading ASX 200 shares on Thursday

Rio Tinto (ASX:RIO) share price slides as iron ore value continues tumbling
2 buy-rated small cap ASX shares

Here are the top 10 ASX 200 shares on Thursday – yes there were some

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!